(RTTNews) - GE Healthcare said Monday that the U.S. Food and Drug Administration approved Clariscan, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio ...

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...

Evidence of gadolinium deposits in neuronal tissues following intravenous (IV) gadolinium-based contrast agents have been found, researchers from the Mayo Clinic reported. Findings have been published ...

Magnetic resonance imaging (MRI) contrast agents have had a significant impact on the value of MRI by enhancing the visibility of internal bodily structures such as organs and vasculature. MRI ...

New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE Healthcare’s innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI ...

A surgical predictive risk model of in-hospital mortality for primary resectable lung cancer: Statistical analysis of 8,796 patients from a nationally representative database ...

A twist on magnetic resonance imaging that does not require gadolinium contrast appears to be as effective as standard imaging at detecting prostate cancers, according to a new study in JAMA. Experts ...

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...